(1)
DUBLIN, Feb. 2, 2021 /PRNewswire/ Eurofins is making new assays for the identification of B.1.1.7 (UK) and B.1.351 (South Africa)/B.1.1.248 (Brazil) variants with a one hour run time available for free to public health institutions who do not have capabilities to rapidly identify the presence of these variants.
SARS-CoV-2 belongs to a group of RNA viruses that exhibit spontaneous mutations. Some alarming variants have recently been identified including:
The new lineage B.1.1.7 first identified in South England and
t
he lineages B.1.351 and B.1.1.248 initially discovered in South Africa and Brazil, respectively. All of these variants appear to be more infective.
Share this article
(PRNewsfoto/Eurofins U.S. Clinical Diagnost)
FRAMINGHAM, Mass., Dec. 16, 2020 /PRNewswire/ Eurofins announces that its FDA-authorized At-Home COVID-19 Nasal PCR Test is now being offered in all 50 states. Previously, the At-Home test was not available for use in New York, New Jersey, Rhode Island and Maryland. The Emergency Use Authorization ( EUA ) authorized self-collection kit gives consumers a minimally invasive, convenient and quick option to test from the comfort of their home. Results are provided via email link within 24 hours of sample receipt.
Available through the Eurofins at-home health testing company, Clinical Enterprise Inc., through its empowerDX business line, the At-Home test can be ordered online (https://empowerdxlab.com/) and will ship to your home or business. After completing a questionnaire, qualified consumers will receive the sample collection kit. Patients who are enrolled in Medicare, Medicaid, or other valid third-party